Early Stage

Somewhat sure of commercial potential, but need to quantify attractiveness to payer and pricing

Early stage innovators may not understand what impacts payers give more and less weight to in their technology adoption processes.

ASSESS provides access to experts with real insight in to the importance of that different payers attach to health gain, green and grey dollar cost savings, budget impact, equity and implementation considerations, and how these impact on the acceptability of target prices.

Learn more
How We Do It

Analytic approach to informing foundational decisions

At each stage of the Commercialization Journey, life sciences innovators have key questions, and analytic and decision support needs, that can be answered and provided by those with expertise in health technology assessment and health economics.

team
Photo by Hester Qiang on Unsplash

Stage based insights and methods

Insights help to inform strategy and focus evidence generation activities on those that are the most valuable, and analyses and evidence generated support communication with investors, end users and payers.

ASSESS and a global network of experts bring methods and insights from health technology assessment and economic modelling to help innovative companies make informed strategic decisions early in technology development. Innovators at the Early Stage can have decisions informed by an assessment of the potential return-on-investment (ROI) for the intended payer with technology adoption, as well as the value-based price (collectively the technology Adoption Case).

Quantified Payer ROI Analysis

This analysis supports innovators understanding of the potential for technologies in development to be procured/obtain reimbursement from intended payers.

Early economic evaluation uses techniques from health economic modelling to quantify the potential for technology to be attractive to payers.

This type of analysis can inform on the potential for technology to be cost-savings to the payer, in a manner that is harvestable from budgets, and can describe the effectiveness the technology must demonstrate in order to be considered cost-effective and attractive.

Market Segmentation Patient Target Calculation Market Sizing
team
Photo by Stephen Dawson on Unsplash

Value-Based Pricing Assessment

This assessment supports innovators to understand the range of technology pricing opportunity that is likely to be acceptable to payers, in order to reasonably estimate revenue potential and commercial viability.

Early economic evaluation uses techniques from health economic modelling to determine the range of value-based pricing available to the technology, given its potential impact on health and costs in target health systems.

  • Trial Objectives
  • Implementation Strategies
  • Study Design
  • Outcome Measures
Testimonials

What our clients say

“We enjoyed working with and recommend ASSESS. They helped us to complete an early economic analysis, including a variety of sensitivity analyses, to assist us to demonstrate that our product is extremely cost effective in our target population.”

Rory St. Clair
VP Operations

“We are extremely satisfied with the work done and have already recommended the service to others.

This program has been invaluable to us, I can't say enough to recommend it - this kind of evidence is vital to digital health sales and incredibly hard to find. We plan to include the service in major research projects in the future to demonstrate the economic impact of our interventions.”

Rob Attwell
COO

“The ASSESS project provided NURA with robust, real-world data to substantiate the health economic rationale underlying our pricing structure. This data will be instrumental in presenting our value proposition to hospital decision-makers and investors.”

Georgia Powell
Co-founder & CEO

“Our team was very happy with the level of thoroughness and rigor of the work and deliverables from the ASSESS team, as well as their communication. We would recommend the service to other organizations given the ease of working with the ASSESS team and the rigor of their work.”

Tanya Scarapicchia

Contact Us

Contact us to learn more about how insights from ASSESS can help your organization make informed strategic decisions that help maximize commercial success of technology in development.

Let's talk